Second-look TURBT showed limited value in altering outcomes for high-grade Ta bladder cancer after complete resection.

TURBT, or transurethral resection of bladder tumor, is a common, minimally invasive outpatient procedure used to diagnose, stage, and treat bladder cancer.

TURBT was associated with persistent sexual dysfunction in men, pointing to the importance of incorporating sexual health into postoperative evaluation.

Re-TURBT was performed in 10% of patients receiving neoadjuvant mitomycin C and in 19% of those in the control group. Within the neoadjuvant mitomycin C group, results of pre-mitomycin C biopsies ...

This approach to initial staging made it possible for about 17% of patients to safely skip TURBT, said Nicholas D. James, PhD, of the Institute of Cancer Research in London, and colleagues.

Repeat transurethral resection of bladder tumor (TURBT) prior to radical cystectomy does not improve survival in cT2N0 muscle-invasive bladder cancer, a new study concludes.

Depending on the disease risk, TURBT on its own can offer similar protection from disease recurrence. Not having a comparator makes it difficult to know if there's really any value-add over TURBT.

TURBT is the main treatment for non muscle invasive bladder cancer. You usually have this operation as your first treatment. TURBT can also diagnose bladder cancer and find out whether the cancer has ...

TURBT is the current standard of care (SOC) for patients with low-grade, intermediate-risk NMIBC; however, the study authors noted that this treatment method provides inadequate disease control and ...

On day 2 of an FDA advisory meeting to consider a new treatment for non–muscle invasive bladder cancer, an FDA official warns of the implications of approving based on a single-arm trial.